Literature DB >> 35711817

Targeting Nuclear Receptors for Chronic Inflammatory Pain: A Potential Alternative.

Kristine Griffett1.   

Abstract

Pain is the unpleasant consequence of detrimental neuronal activity that can be triggered by chronic inflammation, noxious stimuli, and nerve damage. In the case of chronic inflammatory pain, the establishment and maintenance of pain states often depend on the chronic activation and immune response occurring at the site of the peripheral nerve injury. Many current analgesic drugs lack efficacy in long-term pain management. Targeting the nuclear receptor family of transcription factors may provide a novel avenue for the treatment of chronic inflammatory pain. Peroxisome proliferator-activated receptor (PPAR) ligands have demonstrated efficacy in several diabetic-related neuropathic pain models, while the REV-ERB receptors play a key role in the regulation of both P2X7 receptor expression and NLRP3 inflammasome expression and activation. As such, activating the REV-ERB receptor may provide an anti-inflammatory and analgesic option for chronic inflammatory pain sufferers.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35711817      PMCID: PMC9194933          DOI: 10.1021/acsptsci.2c00063

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  30 in total

1.  Exercise Induction of Key Transcriptional Regulators of Metabolic Adaptation in Muscle Is Preserved in Type 2 Diabetes.

Authors:  Rugivan Sabaratnam; Andreas J Pedersen; Tilde V Eskildsen; Jonas M Kristensen; Jørgen F P Wojtaszewski; Kurt Højlund
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 2.  Inflammation: therapeutic targets for diabetic neuropathy.

Authors:  Jiyin Zhou; Shiwen Zhou
Journal:  Mol Neurobiol       Date:  2013-08-30       Impact factor: 5.590

Review 3.  The NLRP3 Inflammasome as a Pharmacological Target.

Authors:  Carlo Marchetti
Journal:  J Cardiovasc Pharmacol       Date:  2019-10       Impact factor: 3.105

4.  REV-ERBα agonist SR9009 suppresses IL-1β production in macrophages through BMAL1-dependent inhibition of inflammasome.

Authors:  Huiling Hong; Yiu Ming Cheung; Xiaoyun Cao; Yalan Wu; Chenyang Li; Xiao Yu Tian
Journal:  Biochem Pharmacol       Date:  2021-07-26       Impact factor: 5.858

5.  Novel Approaches, Drug Candidates, and Targets in Pain Drug Discovery.

Authors:  Samuel Obeng; Takato Hiranita; Francisco León; Lance R McMahon; Christopher R McCurdy
Journal:  J Med Chem       Date:  2021-05-06       Impact factor: 7.446

6.  P2X7-dependent release of interleukin-1beta and nociception in the spinal cord following lipopolysaccharide.

Authors:  Anna K Clark; Amelia A Staniland; Fabien Marchand; Timothy K Y Kaan; Stephen B McMahon; Marzia Malcangio
Journal:  J Neurosci       Date:  2010-01-13       Impact factor: 6.167

7.  Evidence for a distinct neuro-immune signature in rats that develop behavioural disability after nerve injury.

Authors:  Paul J Austin; Annika M Berglund; Sherman Siu; Nathan T Fiore; Michelle B Gerke-Duncan; Suzanne L Ollerenshaw; Sarah-Jane Leigh; Priya A Kunjan; James W M Kang; Kevin A Keay
Journal:  J Neuroinflammation       Date:  2015-05-20       Impact factor: 8.322

8.  SR9009 administered for one day after myocardial ischemia-reperfusion prevents heart failure in mice by targeting the cardiac inflammasome.

Authors:  Cristine J Reitz; Faisal J Alibhai; Tarak N Khatua; Mina Rasouli; Byram W Bridle; Thomas P Burris; Tami A Martino
Journal:  Commun Biol       Date:  2019-10-03

Review 9.  Update of P2X receptor properties and their pharmacology: IUPHAR Review 30.

Authors:  Peter Illes; Christa E Müller; Kenneth A Jacobson; Thomas Grutter; Annette Nicke; Samuel J Fountain; Charles Kennedy; Günther Schmalzing; Michael F Jarvis; Stanko S Stojilkovic; Brian F King; Francesco Di Virgilio
Journal:  Br J Pharmacol       Date:  2020-12-21       Impact factor: 9.473

10.  REV-ERBα Regulates TH17 Cell Development and Autoimmunity.

Authors:  Mohammed Amir; Sweena Chaudhari; Ran Wang; Sean Campbell; Sarah A Mosure; Laura B Chopp; Qun Lu; Jinsai Shang; Oliver B Pelletier; Yuanjun He; Christelle Doebelin; Michael D Cameron; Douglas J Kojetin; Theodore M Kamenecka; Laura A Solt
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.